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Bitter Taste Receptors for Asthma
Therapeutics
Ajay P. Nayak, Sushrut D. Shah, James V. Michael and Deepak A. Deshpande*
Division of Pulmonary, Allergy and Critical Care Medicine, Center for Translational Medicine, Department of Medicine, Jane
and Leonard Korman Respiratory Institute, Thomas Jefferson University, Philadelphia, PA, United States
Clinical management of asthma and chronic obstructive pulmonary disease (COPD) has
primarily relied on the use of beta 2 adrenergic receptor agonists (bronchodilators)
and corticosteroids, and more recently, monoclonal antibody therapies (biologics)
targeting specific cytokines and their functions. Although these approaches provide
relief from exacerbations, questions remain on their long-term efficacy and safety.
Furthermore, current therapeutics do not address progressive airway remodeling (AR),
a key pathological feature of severe obstructive lung disease. Strikingly, agonists of the
bitter taste receptors (TAS2Rs) deliver robust bronchodilation, curtail allergen-induced
inflammatory responses in the airways and regulate airway smooth muscle (ASM) cell
proliferation and mitigate features of AR in vitro and in animal models. The scope
of this review is to provide a comprehensive and systematic insight into our current
understanding of TAS2Rs with an emphasis on the molecular events that ensue TAS2R
activation in distinct airway cell types and expand on the pleiotropic effects of TAS2R
targeting in mitigating various pathological features of obstructive lung diseases. Finally,
we will discuss specific opportunities that could help the development of selective
agonists for specific TAS2R subtypes in the treatment of asthma.
Keywords: TAS2R, airway smooth muscle, gustducin, asthma, SCC, relaxation
INTRODUCTION
Gustatory chemosensory perception within the oral cavity of vertebrates allows for discernment of
bitter, sweet, sour, salty, and umami (savory taste associated with monosodium glutamate) stimuli
associated with ingested foods. This sensation is communicated either through non-receptor
or receptor mediated mechanisms and is commonly described as “taste.” While salt and sour
taste perceptions are hypothesized to be driven by epithelial sodium channel (ENaC) and acid-
sensing ion channels (ASICs), respectively, (Heck et al., 1984; Kinnamon et al., 1988; Ugawa et al.,
1998), sweet, umami and bitter sensations are mediated by oligomeric G protein-coupled receptor
(GPCR) isoforms (Adler et al., 2000; Gilbertson et al., 2000; Sainz et al., 2001). Collectively, these
chemoreceptors and taste associated-ion channels have been comprehensively studied on taste cells
which are organized in taste buds within the four different gustatory papillae on the dorsal surface
of the mammalian tongue. Chemoperception of taste is initiated by interaction of specific taste
stimulus with the highly specialized cognate receptors on type II taste cells on the tongue and
subsequent transmission of signals to the brain through various cranial nerves (Lee and Cohen,
2015). Evolutionarily, perception of taste (along with olfaction) has been considered to provide
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dietary advantage since it may indicate whether a particular food
is corrupted and potentially harmful for consumption.
Studied predominantly within the oral cavity, surprisingly
taste receptors have been recently described in extra-oral
physiological systems (respiratory, gastrointestinal, nervous,
circulatory, dermal, and hematopoietic), indicating that taste
receptors have adaptive functions. Specifically, bitter taste
receptors (TAS2Rs) have been identified in various extra-oral
tissues, including gut, pancreas, testes, lungs, and bladder
(Sternini et al., 2008; Deshpande et al., 2011; Clark et al.,
2012; Xu et al., 2013; Wolfle et al., 2016). TAS2Rs impart
distinct biological functions within these different tissue
environments, emphasizing physiological layering and versatility.
Most importantly for the scope of discussion here, the ectopic
distribution of TAS2Rs in upper and lower respiratory structural
(epithelial and airway smooth muscle cells) and immune cells has
also been described recently (Deshpande et al., 2011; Clark et al.,
2012; Lee and Cohen, 2015). In this review, we will discuss TAS2R
biology in distinct cell types associated with the respiratory
system, the specific signaling events that ensue TAS2R activation,
and the physiological outcomes in cells (in vitro) and integrative
model systems (ex vivo and in vivo) relevant to the pathology of
obstructive lung diseases.
TAS2Rs IN AIRWAY AND IMMUNE
CELLS: SUBTYPES AND
PHYSIOLOGICAL FUNCTIONS
TAS2R Expression in Distinct Airway Cell
Types
In lungs, TAS2R expression has been confirmed in multiple
airway cell types including airway smooth muscle (ASM)
cells, distinct epithelial cell subtypes as well as resident
(macrophages) and migratory hematopoietic (neutrophils, mast
cells, lymphocytes) inflammatory cells (Shah et al., 2009;
Deshpande et al., 2011; Maurer et al., 2015; Tran et al., 2018). In
this section we will provide a brief overview of TAS2R expression
in individual cell types.
Airway Smooth Muscle
In isolated ASM cells from healthy human donors, mRNA
transcripts have been confirmed for multiple TAS2R subtypes
(Deshpande et al., 2010). Transcripts of different TAS2Rs were
confirmed in ASM tissues freshly dissected from human lungs.
Specifically, transcripts of TAS2R10, TAS2R14, TAS2R31 are
highly expressed in donor ASM cells with 3 to 4-fold higher
levels relative to ADRB2 (which encodes for the β2 adrenergic
receptor). Transcripts of other TAS2Rs such as TAS2R5, TAS2R4,
and TAS2R19 are also expressed at higher levels than ADRB2.
In subsequent years, investigators have reported TAS2Rs in ASM
isolated from guinea pigs and mice, thus providing useful in vivo
and ex vivo systems to study the role of TAS2Rs in ASM cells
(Pulkkinen et al., 2012; Zhang et al., 2013; Tan and Sanderson,
2014). Specifically, in these studies, TAS2R4, TAS2R14, and
TAS2R10 have been described in rodent ASM and TAS2R107
was shown in murine ASM. Immunofluorescence studies in
both isolated ASM cells and tissue slices obtained from human
and rodent lungs have confirmed the expression of different
subtypes TAS2Rs at protein level. These findings suggest that the
expression of TAS2Rs on ASM is evolutionarily conserved across
multiple species. Of note, TAS2R subtypes are found in smooth
muscle of other organs including vasculature, gastrointestinal
tract and bladder and play a role in the physiological regulation
of multiple organ systems (e.g., gastric emptying, vascular tone
and bladder contractility) (Lund et al., 2013; Avau et al., 2015; Liu
et al., 2017; Zhai et al., 2016).
Airway Epithelial Cells
Within the nasal cavity many cells that express TAS2Rs have
been shown to be gustducin-positive and isolated cells have
been confirmed for expression of TAS2Rs at transcript level
(Finger et al., 2003; Shah et al., 2009; Wu et al., 2012; Figure 1).
Specialized ciliated epithelial cells and solitary chemosensory
cells (SCCs) express various TAS2R isoforms that are capable of
recognizing specific chemical constituents within inhaled toxins
and acyl-homoserine-lactones (AHLs) released by microbes.
SCCs comprise 1% of total respiratory surface area (Workman
et al., 2015) and express multiple TAS2R subtypes that are
responsive to bitter tastants. SCCs, however, do not express
TAS2R38, which is found on ciliated epithelial cells (Lee
et al., 2012, 2014). For additional details on SCCs and their
role in chemo-sensation and other physiological processes, the
readers are referred to other reviews (Sbarbati and Osculati,
2003; Barham et al., 2013). In addition to SCCs, specialized
chemosensory cells called brush cells (BCs) also express TAS2Rs
(Saunders et al., 2013). TAS2Rs have also been shown to be
expressed by motile cilia of the human airway epithelial cells
(Shah et al., 2009). Gustducin-expressing epithelial cells are
not limited to humans and have been reported to be scattered
throughout the nasal epithelium in other species including
rodents (Finger et al., 2003). Unlike ASM cells, expression of
TAS2Rs on airway epithelium is restricted to specialized areas
suggesting engagement of TAS2Rs in esoteric physiological and
pathophysiological functions.
Immune Cells
In addition to structural cells of the lung tissue, TAS2Rs have also
been identified in tissue resident and lung infiltrating immune
cells (Orsmark-Pietras et al., 2013; Ekoff et al., 2014). TAS2Rs
have been confirmed at transcript level using genome-wide
expression analyses of isolated blood leukocytes. Furthermore,
the expression of 3 TAS2Rs (13, 14, and 19) has been shown to
be significantly increased in asthmatics (Orsmark-Pietras et al.,
2013). In the same study, lymphocytes were demonstrated to have
higher expression of many TAS2Rs relative to monocytes and
neutrophils, with TAS2R10 expression significantly upregulated
in lymphocytic populations. Additionally, TAS2R38 has been
reported in lymphocytes with high level of expression in
CD4+ T lymphocyte populations, with extensive phenotyping
revealing that the expression levels are higher in activated
and memory T cell populations relative to naïve CD4+ T
cells (Tran et al., 2018). In addition to lymphocytes, TAS2Rs
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FIGURE 1 | Expression of TAS2Rs and distinct functional outcomes of TAS2R agonism in airway cell types. Studies have demonstrated that different TAS2R
subtypes are expressed on solitary chemosensory cells, ciliated epithelial cells, airway smooth muscle cells and immune cells. Proximal signaling events following
TAS2R activation are invariant in taste cells and non-gustatory systems such as respiratory system. Moreover, these receptors have been evolutionarily engineered to
adapt to the tissue environment. Consequently, TAS2R activation results in diverse functional outcomes depending on the cell type. While in taste cells, activation of
TAS2Rs results in sensation of bitter taste, in epithelial cells and immune cells TAS2Rs play a crucial role in recognizing microbial products and mounting nuanced
antimicrobial responses, specifically increased ciliary beat frequency, mucus clearance or antimicrobial nitric oxide generation. In ASM cells, TAS2Rs can be
stimulated to induce ASM relaxation, bronchodilation, and inhibition of cellular proliferation. These functional outcomes of TAS2R activation in airway and immune
cells prompt at potential therapeutic utility of the TAS2R agonism in obstructive lung diseases such as asthma.
have also been reported in monocytic and granulocytic innate
immune cells (Maurer et al., 2015; Gaida et al., 2016). Of
particular interest, TAS2R38 expression has been reported in
neutrophils by multiple investigators and has gained significant
interest owing to its role in promoting antimicrobial action
(Maurer et al., 2015; Gaida et al., 2016). Finally, nine distinct
TAS2R subtypes have been reported in mast cells, with TAS2Rs
4, 46, and 14 expressed at high levels (Ekoff et al., 2014).
Presence of TAS2Rs on immune cells opens a new avenue for
therapeutic targeting in airway inflammatory diseases such as
asthma (Figure 1).
Functional Effects of Stimulation of
TAS2Rs in Airway Cells
Airway Smooth Muscle
Relaxation
Activation of TAS2Rs on ASM cells results in robust relaxation
(Figure 1), perhaps a serendipitous observation that attracted
the attention of researchers from academia and pharmaceutical
industry. The proximal signaling events that ensue TAS2R
activation in ASM cells are marked by increased [Ca2+]i
in ASM cells. Initially, it was presumed that the spike in
[Ca2+]i in ASM cells following TAS2R activation by bitter
taste compounds could result in ASM contraction (Deshpande
et al., 2010). This is because, in cultured human ASM cells
the magnitude of [Ca2+]i transients evoked by bitter tastants
is comparable to that of Gαq-coupled bronchoconstrictors,
histamine, and bradykinin (Deshpande et al., 2010). Constituents
of environmental pollutants could be presumably bitter
tasting compounds and may engage TAS2Rs in airways and
promote ASM contraction and consequently the physiological
rejection of inhaled toxicants. Surprisingly, stimulation
of TAS2Rs on ASM induces a relaxation response with
substantial reversal of pharmacologically- induced contraction
as demonstrated using isolated intact murine tracheal rings
and human main-stem bronchi (Deshpande et al., 2010;
Zhang et al., 2012, 2013). Further, microrheological techniques
have demonstrated that the TAS2Rs expressed on isolated
human ASM cells are primary targets that drive relaxation
response on stimulation with bitter compounds (Deshpande
et al., 2010). It is worth noting that TAS2R-mediated [Ca2+]i
elevation in ASM cells was not observed in freshly isolated
murine ASM cells (Zhang et al., 2013) and in murine lung
slices (Tan and Sanderson, 2014) contrary to what was
seen in cultured human ASM cells. This discrepancy could
stem from difference in the experimental model used in
different studies. Furthermore, TAS2R activation in the
presence of a contractile agonist results in inhibition of
contractile agonist-induced elevation of [Ca2+]i in ASM cells
(Camoretti-Mercado et al., 2015).
Studies on TAS2Rs in ASM cells have shown that agonists
of these receptors can reverse contraction induced by diverse
contractile agonists. In our studies with murine tracheal
tissue, we demonstrated that both quinine and chloroquine
can reverse contraction induced by acetylcholine (ACh) and
serotonin (Deshpande et al., 2010). Similarly, Belvisi et al.
(2011) demonstrated that chloroquine can relax human airways
contracted with histamine or carbachol. Airway relaxation
following TAS2R agonism has since been unequivocally
demonstrated by multiple groups in cells and tissues from
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mice (Deshpande et al., 2010; Zhang et al., 2013; Tan and
Sanderson, 2014), humans (Belvisi et al., 2011; Grassin-Delyle
et al., 2013) and guinea pigs (Pulkkinen et al., 2012) using isolated
airways and lung slices. More recently, it was suggested that
there is heterogeneity among TAS2R agonists in their ability
to inhibit responses induced by distinct contractile agonists
(Camoretti-Mercado et al., 2015). Specifically, chloroquine and
denatonium demonstrate differential regulation of guinea pig
ASM when pre-contracted with different contractile agonists
(Pulkkinen et al., 2012). While denatonium (agonist for T2R4 and
T2R10) preferentially inhibits cholinergic stimulation of guinea
pig trachea, chloroquine (agonist for T2R3 and T2R10) can
inhibit responses initiated by a broad spectrum of contractile
agonists. Similar observations have been reported in human
ASM cells where chloroquine and aristolochic acid (both bitter
tastants) have been shown to differentially inhibit [Ca2+]i
elevation induced by histamine and endothelin (Camoretti-
Mercado et al., 2015). Furthermore, in in vivo mouse model
studies it was further demonstrated that TAS2R agonists reverse
methacholine-induced bronchoconstriction (Deshpande et al.,
2010). Collectively, these findings establish bitter tastants as
novel bronchodilators.
Proliferation
In addition to being the main structural contributor of
hypercontractile pathology in obstructive lung diseases, ASM
cells can demonstrate a hyperplastic/hypertrophic phenotype
that contributes to the airway remodeling in the lungs. This
pathology is marked by an increase in fixed airway resistance
(Nayak et al., 2018). In in vitro and in vivo (described in detail
in later section) studies, agonists of the bitter taste receptor have
demonstrated promising antiproliferative effects (Sharma et al.,
2016). Our studies and a recent study from Liggett’s laboratory
demonstrated that bitter taste receptor agonists such chloroquine,
quinine and saccharin inhibit growth factor (PDGF)-induced
ASM cell proliferation in vitro (Sharma et al., 2016; Kim et al.,
2019). In murine model of asthma, studies further demonstrated
mitigation of ASM cell proliferation by bitter tastants providing
in vivo evidence for anti-mitogenic effect of TAS2R agonists
(Sharma et al., 2017). Collectively, TAS2R agonist inhibit both
ASM contraction and proliferation providing an opportunity to
overcome two key features of asthma with TAS2R agonism.
Airway Epithelial Cells
Multiple epithelial cell types possess TAS2R and the key
components of the signaling machinery that facilitate
intracellular calcium signaling in response to stimulation
by bitter agonists (i.e., gustducin, PLCβ2, TRPM5, and IP3R3)
(Finger et al., 2003; Tizzano et al., 2006, 2011; Merigo et al., 2007;
Gulbransen et al., 2008; Figure 1). Consistent with their ability
to promote repulsive responses to noxious stimuli, TAS2Rs
on upper airway (nasal) epithelial cells play a role in innate
recognition and removal of harmful pathogens thus promoting
immunity. This biological response to microbial secondary
metabolites requires PLCβ2 and TRPM5 (Lee et al., 2014).
SCCs regulate respiratory rate owing to their close proximity
to parasympathetic nerve terminals and ability to release
acetylcholine (ACh) (Krasteva et al., 2011, 2012). Stimulation
of TAS2Rs on SCCs stimulates release of the neurotransmitter
acetylcholine, which drives innate defenses by either eliciting a
neurogenic inflammation or depressing respiration rate to limit
continued inhalation of foreign insult (Finger et al., 2003; Tizzano
et al., 2010; Krasteva et al., 2011, 2012; Saunders et al., 2014).
In sinonasal epithelial cells, activation of TAS2R38 increases
mucociliary clearance and directly kills bacteria suggesting
bactericidal effect of TAS2Rs. Activation of TAS2Rs on human
mucus secreting ciliated epithelial cells with bitter tastants results
in an elevation of intracellular calcium, increased ciliary beat
frequency and improved mucus clearance (Shah et al., 2009).
TAS2Rs are located both extracellularly on the motile cilia and on
the apical membrane of the cell. Receptor activation on ciliated
epithelial cells may also result in induction of anti-microbial
nitric oxide (Lee et al., 2012).
Within the nasal respiratory epithelium, chemosensory
receptors are located on (1) a specialized population of trigeminal
chemosensory cells that provide innate defense whereby inhaled
toxic dusts or aerosols can trigger a physiological response
which causes respiratory reflexes (Kinnamon et al., 1988; Lee
et al., 2014), (2) SCCs that are uniquely positioned in close
proximity to parasympathetic (vagus) nerve terminals (Ugawa
et al., 1998; Krasteva et al., 2011, 2012; Saunders et al., 2013,
2014), (3) mucus producing ciliary epithelial cells that facilitate
mucus clearance (Shah et al., 2009). Therefore, airway epithelial
TAS2Rs play critical role in multitudes of airway pathologies.
In the context of allergic airway diseases, certain microbes
(such as molds) can be major sources of potent allergens that
may exacerbate underlying asthma. Innate recognition of such
toxic dusts and microbes could potentially help protecting the
respiratory system from constant damage. Further, chemosensory
cells in airway epithelium may also act as focal point of initiation
and orchestration of allergen-induced type 2 immune response
similar to what has been shown for tuft cells (chemosensory
cells of gastrointestinal tract) in mediating parasite-induced Th2
immune response (Luo et al., 2019).
Immune Cells
Similar to epithelial cells, immune cells serve a critical function of
maintaining homeostasis in tissue environments by neutralizing
foreign insults. Immune cells are primarily armed with multiple
cell surface receptors (TLRs and CLRs) and cytosolic proteins
(cryopyrin or NALP3) that recognize specific pathogen associated
molecular patterns (PAMPs). Immune cells also express TAS2Rs
that further consolidate their ability to recognize microbial
products and mount the appropriate response. In IgE-receptor–
activated primary human mast cells, TAS2R agonists are found
to inhibit the release of histamine and prostaglandin D2 (Ekoff
et al., 2014). TAS2R agonists inhibit the release of multiple
proinflammatory cytokines and eicosanoids in human blood
leukocytes (Orsmark-Pietras et al., 2013). Bitter tastants (such
as chloroquine, colchicine, erythromycin or ofloxacin) can
inhibit cytokine release from tissue macrophages, myeloid-
derived cell lines, circulating monocytes and monocyte-derived
macrophages/dendritic cells (Jeong and Jue, 1997; Ianaro et al.,
2000; Yasutomi et al., 2005; Jang et al., 2006; Ogino et al., 2009;
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Schierbeck et al., 2010; Vrancic et al., 2012). In addition to
inhibiting cytokine production, our study in isolated human
peripheral blood neutrophils suggest that activation of TAS2Rs
results in inhibition of migration of immune cells (Sharma
et al., 2017). Overall the studies noted above suggest that
TAS2R agonism can inhibit cytokine/chemokine production
and inflammatory cell chemotaxis resulting in a robust anti-
inflammatory effect and promotion of immune tolerance. The
molecular mechanisms underlying the anti-inflammatory effects
of TAS2R activation need additional investigation.
TAS2R – Receptor Organization, Core
Signaling Events and Related Functional
Outcomes
G protein-coupled receptors mediate signal transduction in
all physiological systems and are activated by a wide range of
endogenous ligands including chemicals, peptides and proteins.
They are often critical for maintaining homeostatic functions
in various tissue systems and consequently have been targeted
for drug discovery in various diseases. Engagement of activating
molecules (i.e., agonists) to the GPCR induces a conformational
change in the receptor within the plasma membrane, allowing
for binding of cognate heterotrimeric G proteins (Gq, Gs,
Gi subunits) which initiates downstream signaling and
accumulation of second messengers (e.g., Ca2+, cAMP)
that culminates in distinct biological outcomes (Billington and
Penn, 2003; Deshpande and Penn, 2006). Receptors of bitter
taste sensation belong to the GPCR super-family of proteins
and possess the typical structure of seven plasma membrane-
spanning domains with a short extracellular N-terminal domain
and an intracellular C-terminal domain. However, TAS2Rs differ
from prototypical GPCRs in that TAS2Rs primarily associate
with the cognate heterotrimeric G protein (gustducin) composed
of Gαgust and Gβγ subunits (Deshpande et al., 2010; Tizzano
and Finger, 2013; Figure 1). Although gustducin expression is
demonstrated in airway epithelial and smooth muscle cells, the
functional role of Gαgust in these non-gustatory cells remains
unclear. Recently, it has been suggested that TAS2R signaling in
ASM does not involve Gαgust but instead ASM TAS2Rs couple
to Gαi subunits to induce airway relaxation (Kim et al., 2017).
However, additional studies are needed to ascertain the role
of Gαgust or other Gαi G proteins in airway relaxation and
bronchodilation ex vivo and in vivo using knockout mice. It is
also worth noting here that the Gαgust is highly homologous to
other members of the Gi family of G proteins.
Typically, ligand interaction with the receptor results in
a conformational change of the receptor and subsequent
association and then the dissociation of the Gα and Gβγ subunits.
The conformation states of TAS2Rs with or without agonist
activation is not well understood. Moreover, each of the TAS2R
subtypes can be activated by multiple, chemically diverse group of
agonists making the structure-activity relationship very complex.
However, recent advances in computational analysis has provided
hints at structural requirements of different domains on TAS2R
for agonist binding (Born et al., 2013; Di Pizio and Niv, 2015;
Di Pizio et al., 2016). Presumably, the disengaged G protein
subunit mobilizes the membrane-associated phospholipase Cβ
2 (PLCβ2) enzyme, which in turn catalyzes the cleavage of
the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2)
into second messengers, inositol 1,4,5-triphosphate (IP3) and
diacylglycerol (DAG) (Billington and Penn, 2003). Cytosolic
interactions between IP3 and its receptor IP3R, an ion
channel present on sarcoplasmic reticulum could result in
elevation of [Ca2+]i. In taste cells, this signaling cascade
results in elevation of intracellular calcium, opening of TRPM5
channel and in influx of Na+ causing depolarization at the
cellular membrane resulting in release of ATP which acts
as a neurotransmitter by activating purinergic receptors on
nerves associated with taste buds. The resulting impulse is
transmitted to the brain as bitter taste sensation (Finger
et al., 2005; Chaudhari and Roper, 2010; Taruno et al.,
2013; Peng et al., 2015). Absence of any of these signaling
proteins, results in loss of sensation of bitter taste suggesting
the necessary role of TAS2R-mediated signal transduction
mechanism involving calcium. This signaling cascade is invariant
and forms the core intracellular response in distinct cell
types, however, the functional outcome is different and is
tailored to the physiological environment wherein these receptors
reside (Figure 1).
Mechanistic Basis of ASM Relaxation by TAS2Rs
Independent research studies have consistently asserted that
TAS2R agonism induces airway relaxation, however, the exact
mechanism(s) by which this occurs is unclear (Figure 2). Detailed
investigation into the mechanism of ASM relaxation induced by
TAS2R activation suggests that unlike activation of β2 adrenergic
receptor by receptor selective agonists, bitter tastants induce
relaxation through mechanisms not dependent on generation
of prototypical Gs-coupled signaling second messengers such
as cAMP and activation of PKA, effects deemed essential for
relaxation of ASM (Deshpande et al., 2010). Furthermore, neither
epithelial cell generated nitric oxide nor PGE2 via activation of
soluble guanylyl cyclase and prostaglandin receptors respectively,
contributes toward TAS2R-mediated airway relaxation.
Findings from multiple groups suggest that TAS2Rs signaling
in ASM cells involves complex interaction of diverse second
messengers. Signaling via TAS2R in ASM is mediated via Gβγ
subunit (contrary to other GPCRs in ASM) similar to what
has been shown in taste cells (Deshpande et al., 2010). Further,
TAS2R-induced ASM relaxation is dependent on activation of
phospholipase C. However, the specific signaling downstream of
PLC activation is somewhat controversial. In cultured ASM cells,
our studies reveal elevation in intracellular calcium concentration
by a variety of bitter tastants including chloroquine, quinine and
saccharine (Deshpande et al., 2010). Although, the accumulation
of [Ca2+]i by bitter tastants and contractile agents such as
histamine evoke differential functional outcomes. One leading
hypothesis is that the stimulation by either agonist drives
distinct spatiotemporal distribution of intracellular calcium.
Stimulation with bitter tastants possibly compartmentalizes Ca2+
near the cell membrane resulting in opening of channels
that collectively contribute to hyperpolarization at the cellular
membrane (Deshpande et al., 2010). A similar mechanism
has been described in neuronal cells where microdomains of
concentrated [Ca2+]i are associated with opening of BKCa
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FIGURE 2 | TAS2R signaling mediating relaxation in ASM cells. Activation of TAS2Rs on ASM cells results in relaxation, however, diversity in proximal signaling
following receptor activation may occur with different agonists and agonist concentrations. Three basic mechanisms of action have been proposed: (1) elevation in
intracellular Ca2+ from SR stores that in turn activate large conductance Ca2+ activated K+ (BKCa) channels, alter membrane potential (hyperpolarize) and relax the
smooth muscle; (2) Gβγ subunit-mediated inhibition of voltage-dependent calcium channel that are activated upon stimulation of ASM cells with contractile agonist
thereby inhibiting calcium elevation and contraction; (3) inhibition of Ca2+ release from IP3 stores by Gq-coupled GPCR agonists thereby attenuating
agonist-induced calcium elevation and contraction.
channels (Fakler and Adelman, 2008). In ASM cells, activation
of TAS2Rs and H1 histamine receptor by ligands (bitter
tastants and histamine, respectively) results in generation of
[Ca2+]i signals within the cell. However, activation of TAS2Rs
results in rapid and localized mobilization of [Ca2+]i unlike
response to histamine, which is predominantly diffused and
delayed. However, in murine ASM cells and lung slices bitter
tastants do not elicit calcium response but inhibit calcium
elevation mediated by contractile agonists (Tan and Sanderson,
2014). Furthermore, a recent study revealed that modulation
of calcium response in ASM is bitter tastant- and contractile
agonist-dependent (Camoretti-Mercado et al., 2015). Calcium
elevation, a rather atypical TAS2R signaling event appears to
be heterogeneous and is restricted to specific combinations
of a select few bitter tastants that may also activate/inhibit
other heterotrimeric Gq or Gi-coupled receptors. Currently,
the specific factors that contribute to the compartmentalization
of [Ca2+]i and generation of possible microdomains remain
unclear. Furthermore, the spatiotemporal dynamics of [Ca2+]i
following activation of TAS2Rs by distinct agonists remain ill-
defined and is a subject of future research.
Studies have shown that downstream of TAS2R activation,
large conductance Ca2+-activated potassium channels (BKCa)
are opened (Deshpande et al., 2010). BKCa channels that
are gated by localized increase in calcium concentration and
membrane potential are expressed on human ASM and are
involved in regulating airway muscle tone (Morin et al., 2007;
Martin et al., 2008). However, others have suggested that
the activation of BKCa channels may not be required for
relaxation by bitter tastants (Zhang et al., 2012). Again, these
discrepancies could arise from experimental models and use
of bitter tastants alone or in combination with contractile
agonist. A study by Zhuge group suggested that TAS2R activation
leads to Gβγ–dependent inhibition of voltage-gated calcium
channels that are required for Gq-coupled GPCR-mediated
calcium elevation and contraction (Zhang et al., 2012). Inhibition
of contractile agonist-induced calcium elevation by TAS2R
activation was also demonstrated by Sanderson group (Tan
and Sanderson, 2014). This study specifically demonstrated
that TAS2R activation leads to Gβγ–dependent inhibition of
IP3-mediated calcium oscillations in murine lung slices. Study
by Tan and Anderson has shown that TAS2R agonists dilate
airways not by increasing [Ca2+]i but through inhibition
of IP3-mediated Ca2+ oscillations induced by contractile
agonists of the Gq-coupled receptors. This limits the pool
of Ca2+ available to sustain the molecular signaling that
contributes to contraction of ASM cells. Another study reaffirms
findings by multiple investigators that TAS2Rs mediate ASM
relaxation by unconventional mechanisms that are typical of
bronchodilators currently in management of obstructive lung
diseases. However, the findings from this group indicate that
TAS2R agonists induce airway relaxation through inhibition
of phosphatidylinositol-3 kinase (PI3K) (Grassin-Delyle et al.,
2013). Specifically, inhibitors of PI3K (wortmannin, PI-828)
potentiate the relaxing capabilities of bitter taste agonists.
Elsewhere, it has been suggested that TAS2Rs regulate ASM
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function not by regulating pharmacomechanical coupling but by
driving actin depolymerization and its subsequent dissociation
from myosin (Tazzeo et al., 2012). While this mechanism has
been specifically demonstrated for caffeine, it is unclear if this is a
universal mechanism across all agonists.
Collectively, while multiple investigations described above
have concluded that stimulation of TAS2Rs results in ASM
relaxation, the specific mechanism/s by which this occurs has
been controversial and has been debated extensively since
the initial reporting of this phenomenon (Deshpande et al.,
2010). The intrinsic heterogeneity within the TAS2R receptor-
agonists combinations overlaid with species-specific variations
in TAS2R expression may account for some of the differences.
For instance, it was demonstrated that while agonist activity on
TAS2R receptors increases [Ca2+]i, this phenomenon may not
be universal for all bitter tasting compounds (Deshpande et al.,
2010; Camoretti-Mercado et al., 2015). Furthermore, the authors
also demonstrated that the choice of pre-contractile agonist could
differentially alter intracellular Ca2+ management in ASM cells
suggesting differential regulation of compartmentalized signaling
in ASM cells. As a consequence of this compartmentalized
spatiotemporal regulation of Ca2+, the membrane potential
changes are distinct (likely involving certain channels). The
study concluded that TAS2R activation results in activation
of principally two distinct pathways based on their efficiency
in managing cellular Ca2+. The pathway that induces Ca2+
accumulation is likely a less efficient pathway since the potency
of agonists to achieve this response is high. Another second
pathway likely competes with contractile agonists for the available
Ca2+ pool, thus driving a competitive inhibition of contraction
(Figure 2). The pharmacological heterogeneity is also further
complicated by the application of a mechanical stress/force
change on ASM tissue in many of the ex vivo physiological
evaluations describing TAS2R function. Another aspect that
could contribute to differences is due to potential off-target
effects of TAS2R agonists that are not completely understood.
One approach that has previously worked for refining our
understanding of heterogeneity in GPCR signaling involves
distinct E-prostanoid (EP) receptor subtypes that bind to the
endogenous ligand prostaglandin E2 (PGE2) resulting in diverse
signaling and functional outcomes. The development of EP
receptor subtype-specific agonists has provided clarity on the
physiological attributes endowed to each receptor (Michael et al.,
2019). Additional efforts that engender the development of
TAS2R receptor subtype specific agonists could potentially clarify
the perplexing signaling differences noted in multiple studies.
Finally, one puzzling aspect of TAS2R physiology in airways
is that while stimulation of TAS2Rs across all species stimulates
airway relaxation, the potency and efficacy of the relaxant
effect is different in mice (including different subspecies)
compared to humans (Deshpande et al., 2010, 2011; Belvisi
et al., 2011; Morice et al., 2011; An et al., 2012a; Zhang et al.,
2012). Broadly, the use of cells/tissues from different species
could potentially explain some of the differences across the
studies. Studies on tissues/cells sourced from human donors
are also often fraught with intrinsic variabilities. Furthermore,
the distribution of specific TAS2R subtypes within the human
bronchial tree is uncharacterized and could possibly account
toward variations. Finally, methodological discordances in
defining baseline contractile tone or resting passive tension could
explain the inconsistencies reported in these findings. In future,
additional studies with more refined receptor subtype-specific
agonists in a unified experimental system are needed to ascertain
the relative contribution of each signal transduction pathway.
Mechanistic Basis of Inhibition of ASM Proliferation
by TAS2Rs
As noted earlier, one promising feature of TAS2R agonists is their
ability to regulate ASM proliferation, a significant advantage over
current asthma medications. Multiple studies have clarified the
signaling mechanisms that regulate ASM proliferation (Sharma
et al., 2016; Pan et al., 2017). Stimulation with growth factors
results in proliferative signaling which are orchestrated and
sustained by activation of distinct pathways. Firstly, growth
factors can activate their cognate tyrosine-kinase receptors and
activate the mitogen-activated protein (MAP) kinase pathway
that promotes cell proliferation. Furthermore, activated receptors
can also recruit cytosolic phosphoinositide-3-kinase (PI3K) that
phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to
form phosphatidylinositol 3,4,5-triphosphate (PIP3), which is a
second messenger that activates protein kinase B (Akt), which
in turn can regulate activation of enzymes and transcription
factors that promote cell growth (Figure 3). Agonists of
TAS2Rs regulate ASM proliferation stimulated by growth
factors by inhibiting specific checkpoints within these pro-
growth pathways (Sharma et al., 2016). Specifically, TAS2R
agonists (chloroquine and quinine) inhibit phosphorylation
of Akt and p70-S6 kinase independent of PIP3 regulation,
suggesting that it occurs downstream of PI3K. Furthermore,
while TAS2R agonists do not inhibit acute activation p42/44
and p38 following stimulation of ASM cells with growth
factors, they inhibit activation of the transcription factors AP-
1 (Activator protein-1), and E2F with an associated decrease in
expression of cell cycle genes including cyclin D1, which are
essential for cell cycle progression (Figure 3). Collectively, these
findings demonstrate significant capability of TAS2R agonists in
regulating ASM cell proliferation. A recent study by Kim et al.
(2019) showed that TAS2R agonists inhibit cell proliferation in
ASM cells obtained from healthy and asthmatic donors, and
TAS2R agonist-induced antimitogenic effect on ASM involves
inhibition of ERK MAP kinase activity in a time-dependent
manner (Figure 3). The authors also demonstrate that different
structurally diverse TAS2R agonists inhibit ASM proliferation
to a different degree suggesting multiple mechanisms may
contribute to the anti-mitogenic effect of TAS2R agonists
(Kim et al., 2019).
More recently, we have shown that in addition to
arresting cell cycle progression, bitter tastants can also alter
mitochondrial function and induce autophagy in ASM
cells (Pan et al., 2017). Specifically, using a combination
of ultrastructural analysis and biochemical approaches
we demonstrate that TAS2R agonists stimulate formation
of autophagosomes to inhibit cell survival (Figure 3).
Furthermore, TAS2R agonists not only decrease mitochondrial
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FIGURE 3 | Anti-proliferative actions of TAS2R agonism in ASM cells. In asthma, secreted growth factors from infiltrating immune cells and resident epithelial cells
can promote ASM cell hyperplasia through PI3 and MAP kinase pathways. Activation of TAS2Rs can regulate ASM cell proliferation by (1) exerting inhibitory action
on cell cycle progression (ERK/MAPK and PI3K) and (2) promoting mitochondrial fragmentation and autophagy, and inhibiting cell survival.
membrane potential and increase ROS generation, they
drive physical changes in mitochondrial structure by
inducing fragmentation. Activation of TAS2Rs increased
expression of Bnip3 and subsequently increased localization
of dynamin-like protein 1 (DLP-1) to mitochondria with
concurrent mitochondrial fragmentation and organelle
dysfunction. These findings demonstrate that the activation
of TAS2Rs induces cell death through diverse mechanisms,
thus making them promising targets for development of
anti-asthma therapy.
Epithelial Cell Function Modulation by TAS2R
Agonists
As noted earlier, the signaling events upon TAS2R activation
are invariant in distinct cell types and results in mobilization
of intracellular Ca2+ from the intracellular stores. However,
there is considerable diversity in specific events downstream
of Ca2+ accumulation within each cell type that contributes
toward innate defense. For e.g., following stimulation by
bitter tastants, sinonasal epithelial cells increase production of
nitric oxide (NO) which can be toxic to invading pathogens
(Lee et al., 2014). In particular, T2R38 has been shown to
directly recognize N-acyl homoserine lactones (AHL) (a bitter
tasting compound) from gram-negative bacteria (Pseudomonas
aeruginosa) (Lee et al., 2012). In gram-negative bacteria and
certain molds, accumulation of AHL serves as a quorum sensing
strategy to regulate biofilm formation which is an assemblage of
microbial cells that is enclosed within a polysaccharide matrix,
and are an important sue toward controlling establishment
of infectious diseases (Donlan, 2002; Taghadosi et al., 2015).
T2R38-AHL interaction yields a Ca2+-dependent nitric oxide
production, increased ciliary beat frequency, and increased
mucociliary clearance of inhaled pathogens. Therefore, the
airway epithelium TAS2R-mediated detection of AHL has an
important role in imparting immunity in the airways, (Tizzano
et al., 2010) in which TAS2Rs serve as pattern recognition
receptors (PRRs) capable of directly engaging the molecules
secreted by pathogens. While activation of TAS2R38 on ciliated
epithelial cells generates bactericidal nitric oxide (Lee et al.,
2012, 2014), stimulation of TAS2Rs on SCCs stimulates release
the neurotransmitter acetylcholine, which drives innate defenses
by either eliciting a neurogenic inflammation or depressing
respiration rate to limit continued inhalation of foreign insult
(Finger et al., 2003; Tizzano et al., 2010; Krasteva et al.,
2011, 2012; Saunders et al., 2014). SCCs also demonstrate
unique cooperative capabilities with adjacent cells to enhance
innate immunity. Activation of TAS2Rs on SCCs stimulates a
Ca2+ wave within the cell, which propagates into adjoining
cells through gap junctions and elicit release of antimicrobial
peptides and β-defensins (Bezencon et al., 2008). In ciliated
epithelial cells, TAS2Rs are located both extracellularly on the
motile cilia and on the apical membrane of the cell, and
receptor activation induces an increase in intracellular Ca2+,
leading to increased ciliary beat frequency, possibly through
induction of nitric oxide and cGMP-protein kinase G pathway
(Salathe, 2007; Figure 1).
As we develop a better understanding of signaling in distinct
airway epithelial cell types in normal and diseased state, and other
factors that could serve as modulators of TAS2Rs signaling, we
may be able to tease out the functional role for specific TAS2R
subtypes and tailor specific agonists for desired physiological
outcomes (Table 1).
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ROLE OF TAS2Rs IN ASTHMA: FINDINGS
FROM ANIMAL MODELS AND HUMAN
CELLS AND TISSUES
Animal Studies
Since their discovery on ASM cells, significant interest has been
stimulated in gaining mechanistic insights into TAS2R signaling
and their biology with an aim to regulate ASM function for
therapeutic relief of obstructive lung diseases. Asthma is the
leading cause of respiratory morbidity and increasing financial
burden especially in developed countries. The disease has reached
epidemic proportions affecting >330 million people worldwide,
with over >250,000 deaths annually. Respiratory distress is
primarily driven by airflow obstruction in the conducting airways
resulting from constriction of ASM of the bronchi, excessive
mucus production and airway inflammation orchestrated by
cellular and secreted mediators. Clinical presentations can be
managed with variable degree of success using therapeutic
options available currently. However, the chronic pathological
state in the lungs drives tissue remodeling (extensive structural
changes to lung tissue), which is challenging to reverse with
modern clinical interventions. Consequently, more than half
the patients affected by asthma (and COPD) exhibit inadequate
control of the disease with current therapeutic regimens (Kraan
et al., 1985; Cheung et al., 1992). TAS2Rs have emerged as
promising novel therapeutic targets owing to their efficacious
bronchodilatory effect.
In the lung, the ASM cells express a repertoire of GPCRs
that when activated modulate airway functions (contractile,
proliferative and synthetic) (Deshpande and Penn, 2006). The
discovery of TAS2Rs in structural and immune cells that drive
TABLE 1 | TAS2R subtypes and broad selectivity of receptor agonists.
Bitter tastants Human receptor Murine receptor
Denatonium TAS2R4, TAS2R10,
TAS2R44
TAS2R108
6-n-propyl-2-thiouracil
(PROP)
TAS2R4, TAS2R38,
TAS2R51, TAS2R61
TAS2R108
Dextromethorphan TAS2R10
β-glucopyranosides TAS2R16
Chloroquine TAS2R10, TAS2R3,
TAS2R39, TAS2R7
Acyl-homoserine
lactones
TAS2R38
Quinine TAS2R10, TAS2R14,
TAS2R4, TAS2R46,
TAS2R39, TAS2R31,
TAS2R7, TAS2R40
Colchicine TAS2R4
Strychnine TAS2R10, TAS2R46
Noscapine TAS2R14
Saccharin TAS2R31
Cycloheximide TAS2R5
Lidocaine TAS2R5
Picrotoxinin TAS2R14
asthma pathology provides an opportunity to mitigate the disease
pathology through development of novel agonists that target
these receptors. The unique physiological properties of TAS2Rs
described here and elsewhere underline their clinical relevance
(Gerthoffer et al., 2013; Liggett, 2013; Pera and Penn, 2016).
Indeed, in severe asthmatics, upregulation of TAS2R sub-types on
peripheral blood leucocytes has been established, underscoring
their pharmacological accessibility as novel therapeutic targets
for asthma (Orsmark-Pietras et al., 2013). Furthermore, in
asthmatic ASM cells and lung tissue slices, neither the expression
nor the signaling and function of TAS2Rs is impaired under
inflammatory conditions (An et al., 2012b; Robinett et al., 2014).
More importantly, TAS2R signal-function outcomes are not
hindered by β2-adrenergic receptor tachyphylaxis (An et al.,
2012b). This is very important because one of the challenges
of using beta agonists is tachyphylaxis due to compromised
functions of β2 adrenergic receptors (Beasley et al., 1999; Salpeter
et al., 2010; Walker et al., 2011). In fact, in murine model, TAS2R
agonists inhibit bronchoconstriction induced by methacholine
efficaciously despite a modest bronchodilation by beta agonist
(Deshpande et al., 2010). Furthermore, in the original article
characterizing TAS2Rs on murine airway smooth muscle cells, a
greater efficacy was demonstrated for bitter tastants in evoking
bronchorelaxation compared to β2 agonists, thus making them
appealing therapeutic candidates for the management of airway
diseases (Deshpande et al., 2010).
In pre-clinical models of allergen-induced (house dust
mite and ovalbumin) asthma, inhalation of bitter compounds
grant bronchoprotection and mitigate allergen-induced airway
inflammation (Deshpande et al., 2010; Sharma et al., 2017).
Treating mice with bitter taste compounds via inhalation
of drug aerosols or intranasal administration results in
ablation of most cardinal features of allergen-induced asthma
(Sharma et al., 2017).
Treatment with chloroquine and quinine also has a profound
effect on infiltration by inflammatory cells in the airways and
within the lung parenchyma. For many years, corticosteroids
(inhaled and systemic) have been mainstay for management
of bronchial inflammation in asthmatics. In addition to being
a viable candidate for ASM relaxation, bitter compounds may
be potentially employed in controlling airway inflammation.
TAS2Rs have been reported on diverse human leukocyte
populations, including circulating granulocytes, T lymphocytes
and monocytes that are all central to asthma pathology
(Malki et al., 2015). Microarray methods to analyze global
changes in gene expression in leukocytes isolated from severe
asthmatics revealed significant upregulation of genes for various
TAS2R subtypes (Orsmark-Pietras et al., 2013). Expression of
multiple TAS2R transcripts is relatively higher in lymphocytes
compared to monocytes or granulocytes, consistent with
another study involving healthy donors (Malki et al., 2015).
There is also a significant shift in expression of TAS2R
subtypes among healthy donors and asthmatics. For instance,
in healthy donors, TAS2R31 transcripts are reportedly most
abundant in isolated circulating cells. Further, while TAS2R10
expression is highest in leukocytes from severe asthmatics, its
expression is lowest among TAS2Rs evaluated in leukocytes
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isolated from healthy donors, indicating regulation of receptor
expression in disease states. Furthermore, TAS2R5 expression in
leukocytes from asthmatics demonstrates significant correlation
with bronchial hyperresponsiveness to methacholine challenge.
In the same study, treatment of leukocytes from whole
blood co-stimulated with LPS and chloroquine or denatonium
resulted in significant inhibition of production of allergic
cytokines IL-4, IL-5 and IL-13. However, few have investigated
the precise mechanism by which TAS2R agonists regulate
immune cell function. Bitter compounds may also limit airway
inflammation by regulating chemotaxis of immune cells and
consequently their recruitment to airways (Sharma et al., 2017).
Inhibition of neutrophil recruitment by TAS2R agonism could
potentially benefit in cases of neutrophilic severe asthma or
in mitigating COPD-associated exacerbations. In both cases
patients respond poorly to inhaled corticosteroids possibly due
to lower expression of glucocorticoid receptors in infiltrating
neutrophils (Plumb et al., 2012).
Another proposed mechanism by which TAS2R agonists
may regulate airway inflammation is by inhibiting IgE receptor
crosslinking-dependent activation of mast cells (MCs) (Ekoff
et al., 2014). Activated MCs are recruited to the ASM
in asthmatics and contribute to airway hyperresponsiveness
(Brightling et al., 2002). Airway infiltrating mast cells influence
ASM function by secreting pro-contractile and proliferative
mediators such as histamines, leukotrienes, tryptase, TGF-β
etc., (Page et al., 2001). Human mast cells isolated from cord
blood express multiple TAS2Rs with TAS2R4 in relatively higher
abundance (Ekoff et al., 2014). Brief treatment of isolated mast
cells with bitter compounds (chloroquine, denatonium) prior
to receptor crosslinking and subsequent activation significantly
inhibits release of histamine and PGD2 indicating a different
mechanism of directly limiting exposure of ASM to pro-
contractile agents. Finally, if epithelial TAS2R subtypes regulate
allergen-induced airway inflammation similar to what has been
shown in parasite-induced Th2 immune response by TAS2Rs
expressed on tuft cells in intestinal tract is not known.
Along with airway inflammation, airway remodeling forms a
crucial hallmark of asthma and chronic obstructive lung diseases.
Remodeling is marked by the increased thickening of ASM
resulting from underlying cellular proliferation. Remodeling
causes conducting airways to be refractory to bronchodilatory
treatments and current treatment regimens have suboptimal
effect on airway remodeling (Bonacci and Stewart, 2006; Halwani
et al., 2010). At clinical level, there is no evidence of significant
inhibitory effects by β agonists, the current gold-standard
of bronchorelaxation on airway remodeling (Halwani et al.,
2010). Bronchial epithelial cells from severe asthmatics release
paracrine factors such as leukotrienes that can regulate ASM
proliferation (Trian et al., 2015) and although antagonists of
CysLTR (montelukast) demonstrate significant anti-mitogenic
effects in vitro and in vivo; no studies in humans have
supported these findings (Halwani et al., 2010; Kelly et al.,
2010). Thus, the therapeutic mitigation of remodeling has
emerged as the “holy grail” of modern-day asthma therapy,
and TAS2Rs provide a golden opportunity for anti-asthma
drug development.
In vitro studies indicate that TAS2R agonists curtail growth
factor-stimulated cell proliferation in ASM cells obtained from
healthy and asthmatic donors alike in a dose-dependent manner
(Sharma et al., 2016; Kim et al., 2019). Mechanistically, TAS2R
agonists inhibit ASM proliferation by multiple mechanisms:
(1) inhibiting the growth factor-activated protein kinase B
(Akt) phosphorylation, (2) inhibiting transcription factors AP-1,
STAT3, E2 factor and NFAT, and (3) inhibiting genes associated
with cell cycle progression. The anti-mitogenic activity of TAS2R
stimulation is independent of PKA activation, which is partly
responsible for similar functions for β2AR (inhibition of ∼25%)
and PGE2 (inhibition of ∼75%) (Kong et al., 2008; Yan et al.,
2011; Sharma et al., 2016). The anti-mitogenic effects of TAS2R
agonists also translate in pre-clinical asthma model. Using a
chronic allergen challenge model, where pathological features of
remodeling can be studied extensively, treatment with bitter taste
compounds (chloroquine and quinine) reverses cardinal features
of airway remodeling (Sharma et al., 2017). Specifically, treatment
with bitter compounds inhibited the expression of calponin,
smooth muscle α-actin, and smooth muscle myosin heavy chain.
Furthermore, levels of MMP-8 (neutrophil collagenase), pro-
MMP-9 (gelatinase) and MMP-12 (macrophage metalloelastase)
were significantly lower in the tissues following treatment with
TAS2R agonists. Collectively, these in vitro and in vivo studies
suggest that TAS2R agonism mitigates features of fibrotic airway
remodeling in asthma.
Treatment with bitter tastants also limits mucus secretion and
goblet cell hyperplasia. As described above, TAS2Rs found on
ciliary epithelial cells control ciliary beat frequency and mucus
clearance. Recent studies suggest that chronic use of beta agonists
promote mucus production potentially contributing to asthma
severity (Nguyen et al., 2017). TAS2R-mediated inhibition of
mucus accumulation favors therapeutic utility of TAS2Rs in
asthma. In prophylactic as well as the treatment model, mice
treated with chloroquine or quinine exhibit significant reduction
in AHR following methacholine challenge (Sharma et al., 2017).
Interestingly, following 3 weeks of treatment with chloroquine
and quinine, the bronchodilatory effect of TAS2R agonists was
not diminished in both PBS and HDM challenged animals.
These data suggest that treatment with TAS2R does not lead to
functional tachyphylaxis.
Collectively, these studies underline the multimodal and
pleiotropic manner in which TAS2Rs can be targeted for asthma
relief and underline the value of developing TAS2Rs as novel
targets for asthma treatment either alone or as an accessory to
current regimens (Figure 1).
RECEPTOR POLYMORPHISMS,
DISEASE ASSOCIATION AND
DEVELOPMENT OF PERSONALIZED
MEDICINE-BASED APPROACHES
To date, over 40 TAS2R genes have been discovered in
humans and mice that encode for proteins of ∼ 300-330
amino acids in length (Bachmanov and Beauchamp, 2007;
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Deshpande et al., 2010). Genes coding for TAS2R subtypes are
distributed on chromosomes 5, 7, and 12 in humans and
chromosomes 2, 6, and 15 in mice. TAS2Rs constitute of
25 subtypes that share 30–70% of their amino acid sequence
homology (Behrens and Meyerhof, 2006). Airway cells express
multiple subtypes of TAS2Rs and up-regulation of TAS2R gene
expression has been reported in leukocytes of subjects with severe
asthma (Pulkkinen et al., 2012). These studies demonstrate that
TAS2Rs contribute to physiological and pathological phenotypes
and that TAS2R genetic variations may contribute to disease
severity and risk. The next critical step in TAS2R research is to
determine which specific TAS2R subtypes are most important
with respect to asthma pathogenesis and potential anti-asthma
therapy. Given the strong evidence that TAS2Rs are involved in
ASM relaxation and ASM proliferation it is logical to assume
that one or more TAS2R genes regulate airway functions. In fact,
recent studies have suggested functional bias among different
TAS2R agonists (Camoretti-Mercado et al., 2015). To further
advance this field of TAS2R research, it is imperative that we
determine specifically which TAS2Rs affect asthma phenotype.
Humans differ in perception of bitter taste which is
attributed to single nucleotide polymorphisms (SNPs) in
TAS2R genes (Table 2; Chamoun et al., 2018). Substantial
literature has been dedicated toward understanding the
functional impact of polymorphisms associated with the T2R38
gene owing to differential ability in taste perception of the
bitter compound phenylthiocarbamide (PTC). Three SNPs
(at positions 49, 262, and 296) of the TAS2R38 gene form
two common haplotypes- either PAV (proline, alanine and
valine) or AVI (alanine, valine, and isoleucine). The PAV
haplotype is considered a “taster,” while inheriting the AVI
haplotype is considered a “non-taster” of bitter taste sensation
(Drayna, 2005). Aside from taste preference, TAS2R SNPs
may contribute to a range of pathologies. For instance, the
TAS2R38 PAV haplotype is correlated with a non-smoking
preference, while the AVI (non-taster) haplotype is more
common among smokers (Risso et al., 2016). Thus, possessing
a specific TAS2R SNP distribution may be beneficial for
aversion of unhealthy habits such as smoking although the
current literature indicates conflicting observations which
limits generalization (Mangold et al., 2008; Keller et al., 2013;
Aoki et al., 2014).
The extent to which polymorphisms of individual TAS2Rs
impact the functionality of cells associated with the respiratory
system is poorly understood. Polymorphisms in TAS2Rs have
been linked to chronic rhinosinusitis (CRS), which is an
inflammatory disorder of the nose and paranasal sinuses
and in asthma (Adappa et al., 2013; Gallo et al., 2016;
Yoon et al., 2016). Some have shown that the rs10246939
SNP (TAS2R38 nucleotide 296 to valine) and other TAS2R
polymorphisms are associated with CRS (Adappa et al., 2013;
Mfuna et al., 2014; Cohen, 2017). However, others have
demonstrated a lack of an association of haplotypes between
CRS patients, either with (CRSwNP) or without (CRSsNP)
nasal polyps, (Gallo et al., 2016). However, at least one study
strongly supports identification of polymorphisms in TAS2Rs
as possible genetic markers to predict outcomes in asthma
TABLE 2 | Taste receptor expressed on ASMs (order of level of expression) and
their genetic variants.
Genes Amino acid variations in protein
TAS2R10 T156M
TAS2R14 T86A, I118V, R174STOP, L201F, K225K
TAS2R31 R35W, M162L, Q217E, A227V, V240I
TAS2R5 G20S, S261?, P113L, Y167C, R209T, R213Q, R294L
TAS2R4 R3Q, Y6S, F7S, F62L, T74M, V96L, S171N, I191V
TAS2R19 F15S, V32I, C106Y, K126Q, R299C
TAS2R3 –
TAS2R20 S75V, K79E, H143Q, H148N, I236V, F252S, R225L
TAS2R45 C76Y, V132M, Q210H, R298T
TAS2R50 S125N, C203Y
TAS2R30 L235F, C238R, C250L, F252L, L281W, P307H
TAS2R9 S104T, K170Q, A187V, L238V, L304F, P309L
TAS2R13 H94R, N149S, N259S
TAS2R42 Y175F, L187L, F196S, G255W, Y265C
TAS2R46 F36V, S201S, L228M, W250STOP, S309P
TAS2R1 P43L, R111H, C141, R206Y
TAS2R8 E16K, M308V
Sourced from GPCR natural variant database (http://nava.liacs.nl) and NCBI SNP
database (dbSNP) (https://www.ncbi.nlm.nih.gov/snp).
(Yoon et al., 2016). Although these association studies have
identified a possible link between TAS2R polymorphisms and
respiratory diseases, a causal link is yet to be established
and the specific contribution toward physiological process
remains to be defined.
CURRENT LIMITATIONS AND FUTURE
OPPORTUNITIES
Advances in our understanding of the underlying mechanisms
that result in airway relaxation and antimitogenic effect
following activation of TAS2Rs has been fraught with
few challenges. The expression of TAS2Rs and relaxant
effect of TAS2R agonists is species dependent (Deshpande
et al., 2011). Furthermore, between mice and humans,
some TAS2Rs lack genetic or pharmacological homologs,
making it difficult to interpret the data from different species.
In vitro and in vivo studies have also identified bitter tasting
ligands for most human, but not murine TAS2Rs (Table 1;
Chandrashekar et al., 2000; Bachmanov and Beauchamp,
2007; Meyerhof et al., 2010). Moreover, receptor specific
knockout models are not practical considering multiple receptor
subtypes can interact with a given ligand. Furthermore,
expansive studies in human tissues and human subjects are
challenging and lack of specific reagents (e.g., receptor-specific
agonists and antagonists) to study TAS2R can all further
complicate interpretation.
In the context of obstructive airways diseases, TAS2Rs
clearly present promise of therapeutic potential due to their
pleiotropic effects on multiple cell types in the lungs that
collectively orchestrate distinct pathological features of the
disease state. Unfortunately, currently available agonists of
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TAS2Rs demonstrate poor affinity to their targets and exhibit
substantial promiscuity in activation of TAS2R subtypes. The
number of compounds that trigger bitter taste sensation are
significantly in excess to the number of TAS2R gene-encoded
proteins, thus emphasizing promiscuity in receptor activation
(Behrens et al., 2004; Di Pizio and Niv, 2015). It is possible
that evolutionarily TAS2Rs have been adapted to be low-affinity
receptors to allow for broad tuning of receptor activation by
heterogeneous insults (Born et al., 2013). Nevertheless, gaining
a better understanding of the structural details of refined
agonists with higher affinity and receptor subtype selectivity will
assist in clarifying the role of individual receptor subtypes on
cell populations critical to asthma pathology. Development of
TAS2R subtype selective agonists could be crucial in resolving
some of these issues but has been hindered primarily due to
unresolved crystal structure of a prototypical receptor. Discovery
of TAS2R agonism in extra-oral tissue systems has generated
significant interest in developing small molecules (agonists
and antagonists) with improved receptor specificity and high-
affinity. To this effect, traditional medicinal chemistry-based
approaches as well as computational modeling have gained
momentum (Di Pizio and Niv, 2015; Di Pizio et al., 2016;
Karaman et al., 2016). Recently, significant strides have been
made in exploiting the unique structural features of TAS2Rs
that enable binding to diverse group of synthetic and naturally
occurring chemical compounds (Di Pizio and Niv, 2015; Di
Pizio et al., 2016; Karaman et al., 2016). Specifically, TAS2R
promiscuity is owing to a large binding pocket and this
structural disposition could possibly allow for engineering of
novel agonists with modifications that could refine our ability
to “fine tune” a “broadly tuned” receptor. These and other
computation approaches may provide additional insight into
TAS2R pharmacology and propel rational drug design.
CONCLUSION
Expression and functional role of TAS2Rs on immune
cells, epithelial cells and ASM suggest that TAS2Rs may
be potential targets for improving bronchodilatory function
and resolving immunological dysregulation and remodeling
changes in individuals with obstructive lung diseases. From
a clinical perspective, the perceived superior efficacy of some
of the bitter tastants, lack of receptor tachyphylaxis, and
availability of a large pool of compounds with established
pharmacokinetic and pharmacodynamics properties are all
attractive (perhaps promising) features of TAS2Rs. TAS2R-
mediated bronchodilatory effect is additive to beta agonist-
induced bronchodilation suggesting potential use of bitter
tastants as adjuvant therapies. Therefore, TAS2Rs are attractive
candidates for multimodal treatment of obstructive lung
diseases either alone or in combination with current therapeutic
regimens. Research into TAS2R agonists with increased
specificity to receptor subtypes will aid in providing clarity to
TAS2R physiology.
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